Cargando…

Normobaric oxygen may attenuate the headache in patients with patent foramen povale and migraine

BACKGROUND AND PURPOSES: There has been both great interest in and skepticism about the strategies for headache inhibition in patients with patent foramen ovale and migraines (PFO-migraine). Furthermore, many questions remain about the fundamental pathophysiology of PFO-migraines. Herein, the inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Mengqi, Lan, Duo, Dandu, Chaitu, Ding, Yuchuan, Ji, Xunming, Meng, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881355/
https://www.ncbi.nlm.nih.gov/pubmed/36707824
http://dx.doi.org/10.1186/s12883-023-03059-z
_version_ 1784879093278310400
author Wang, Mengqi
Lan, Duo
Dandu, Chaitu
Ding, Yuchuan
Ji, Xunming
Meng, Ran
author_facet Wang, Mengqi
Lan, Duo
Dandu, Chaitu
Ding, Yuchuan
Ji, Xunming
Meng, Ran
author_sort Wang, Mengqi
collection PubMed
description BACKGROUND AND PURPOSES: There has been both great interest in and skepticism about the strategies for headache inhibition in patients with patent foramen ovale and migraines (PFO-migraine). Furthermore, many questions remain about the fundamental pathophysiology of PFO-migraines. Herein, the inhibiting effect of normobaric oxygenation (NBO) on PFO-migraine was analyzed. METHODS: This real-world self-control study consecutively enrolled patients during the ictal phase of migraines who had patent foramen ovale (PFO) confirmed by Trans esophageal Ultrasound(TEE). After comparing the baseline arterial oxygen partial pressure (PaO(2)) in their blood gas with that of healthy volunteers, all the patients with PFO-migraine underwent treatment with NBO (8 L/min. for 1 h/q8h) inhalation through a mask. Their clinical symptoms, blood gas, and electroencephalograph (EEG) prior to and post-NBO were compared. RESULTS: A total of 39 cases with PFO-migraine (in which 36% of participants only had a small-aperture of PFO) and 20 non-PFO volunteers entered the final analysis. Baseline blood gas analysis results showed that the PaO(2) in patients with PFO-migraine were noticeably lower than PaO(2) levels in non-PFO volunteers. After all patients with PFO-migraines underwent NBO treatment, 29(74.4%) of them demonstrated dramatic headache attenuation and a remarkable increase in their arterial PaO(2) levels after one time treatment of NBO inhalation (p < 0.01). The arterial PaO(2) levels in these patients gradually went down during the following 4 h after treatment. 5 patients finished their EEG scans prior to and post-NBO, and 4(80%) were found to have more abnormal slow waves in their baseline EEG maps. In the follow up EEG maps post-NBO treatment for these same 4 patients, the abnormal slow waves disappeared remarkably. CONCLUSIONS: Patients with PFO–migraine may derive benefit from NBO treatment. PFOs result in arterial hypoxemia due to mixing of venous blood, which ultimately results in brain hypoxia and migraines. This series of events may be the key pathologic link explaining how PFOs lead to migraines. NBO use may attenuate the headaches from migraines by correcting the hypoxemia.
format Online
Article
Text
id pubmed-9881355
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98813552023-01-28 Normobaric oxygen may attenuate the headache in patients with patent foramen povale and migraine Wang, Mengqi Lan, Duo Dandu, Chaitu Ding, Yuchuan Ji, Xunming Meng, Ran BMC Neurol Research BACKGROUND AND PURPOSES: There has been both great interest in and skepticism about the strategies for headache inhibition in patients with patent foramen ovale and migraines (PFO-migraine). Furthermore, many questions remain about the fundamental pathophysiology of PFO-migraines. Herein, the inhibiting effect of normobaric oxygenation (NBO) on PFO-migraine was analyzed. METHODS: This real-world self-control study consecutively enrolled patients during the ictal phase of migraines who had patent foramen ovale (PFO) confirmed by Trans esophageal Ultrasound(TEE). After comparing the baseline arterial oxygen partial pressure (PaO(2)) in their blood gas with that of healthy volunteers, all the patients with PFO-migraine underwent treatment with NBO (8 L/min. for 1 h/q8h) inhalation through a mask. Their clinical symptoms, blood gas, and electroencephalograph (EEG) prior to and post-NBO were compared. RESULTS: A total of 39 cases with PFO-migraine (in which 36% of participants only had a small-aperture of PFO) and 20 non-PFO volunteers entered the final analysis. Baseline blood gas analysis results showed that the PaO(2) in patients with PFO-migraine were noticeably lower than PaO(2) levels in non-PFO volunteers. After all patients with PFO-migraines underwent NBO treatment, 29(74.4%) of them demonstrated dramatic headache attenuation and a remarkable increase in their arterial PaO(2) levels after one time treatment of NBO inhalation (p < 0.01). The arterial PaO(2) levels in these patients gradually went down during the following 4 h after treatment. 5 patients finished their EEG scans prior to and post-NBO, and 4(80%) were found to have more abnormal slow waves in their baseline EEG maps. In the follow up EEG maps post-NBO treatment for these same 4 patients, the abnormal slow waves disappeared remarkably. CONCLUSIONS: Patients with PFO–migraine may derive benefit from NBO treatment. PFOs result in arterial hypoxemia due to mixing of venous blood, which ultimately results in brain hypoxia and migraines. This series of events may be the key pathologic link explaining how PFOs lead to migraines. NBO use may attenuate the headaches from migraines by correcting the hypoxemia. BioMed Central 2023-01-27 /pmc/articles/PMC9881355/ /pubmed/36707824 http://dx.doi.org/10.1186/s12883-023-03059-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Mengqi
Lan, Duo
Dandu, Chaitu
Ding, Yuchuan
Ji, Xunming
Meng, Ran
Normobaric oxygen may attenuate the headache in patients with patent foramen povale and migraine
title Normobaric oxygen may attenuate the headache in patients with patent foramen povale and migraine
title_full Normobaric oxygen may attenuate the headache in patients with patent foramen povale and migraine
title_fullStr Normobaric oxygen may attenuate the headache in patients with patent foramen povale and migraine
title_full_unstemmed Normobaric oxygen may attenuate the headache in patients with patent foramen povale and migraine
title_short Normobaric oxygen may attenuate the headache in patients with patent foramen povale and migraine
title_sort normobaric oxygen may attenuate the headache in patients with patent foramen povale and migraine
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881355/
https://www.ncbi.nlm.nih.gov/pubmed/36707824
http://dx.doi.org/10.1186/s12883-023-03059-z
work_keys_str_mv AT wangmengqi normobaricoxygenmayattenuatetheheadacheinpatientswithpatentforamenpovaleandmigraine
AT landuo normobaricoxygenmayattenuatetheheadacheinpatientswithpatentforamenpovaleandmigraine
AT danduchaitu normobaricoxygenmayattenuatetheheadacheinpatientswithpatentforamenpovaleandmigraine
AT dingyuchuan normobaricoxygenmayattenuatetheheadacheinpatientswithpatentforamenpovaleandmigraine
AT jixunming normobaricoxygenmayattenuatetheheadacheinpatientswithpatentforamenpovaleandmigraine
AT mengran normobaricoxygenmayattenuatetheheadacheinpatientswithpatentforamenpovaleandmigraine